Beijing Hotgen Biotech Co., Ltd. (SHA:688068)
76.30
-1.23 (-1.59%)
Jun 22, 2026, 11:29 AM CST
Beijing Hotgen Biotech Revenue
Beijing Hotgen Biotech had revenue of 116.03M CNY in the quarter ending March 31, 2026, with 24.44% growth. This brings the company's revenue in the last twelve months to 427.66M, down -12.17% year-over-year. In the year 2025, Beijing Hotgen Biotech had annual revenue of 404.88M, down -20.58%.
Revenue (ttm)
427.66M
Revenue Growth
-12.17%
P/S Ratio
15.94
Revenue / Employee
452.07K
Employees
946
Market Cap
6.82B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 404.88M | -104.90M | -20.58% |
| Dec 31, 2024 | 509.78M | -38.06M | -6.95% |
| Dec 31, 2023 | 547.84M | -3.01B | -84.60% |
| Dec 31, 2022 | 3.56B | -1.81B | -33.76% |
| Dec 31, 2021 | 5.37B | 4.86B | 945.54% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Aurisco Pharmaceutical | 1.68B |
| Xiangxue Pharmaceutical | 1.53B |
| Chengdu Easton Biopharmaceuticals | 1.35B |
| Shanghai Medicilon | 1.26B |
| Chengdu Kanghua Biological Products | 1.20B |
| Bio-Thera Solutions | 980.25M |
| Acrobiosystems | 887.21M |
| GemPharmatech | 830.61M |